A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Summary

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Oncology
• MEK Mutation
• RAF Gene Mutation
• Ras (KRAS or NRAS) Gene Mutation
• Melanoma
• NSCLC
• Glioma
• Solid Tumor, Adult
• MAPK Pathway Gene Mutation

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Nested Therapeutics, Inc

Last updated on ClinicalTrials.gov

April 20, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites